Transition Therapeutics Inc (TTH.TO) Buy,…

Transition Therapeutics Inc (TTH.TO)

0.00

-0.00 (0.00%)

0 watching

COMMENT

As it looked at this in the last couple of months, but likes their Alzheimer's drug. Pure biotech, where they're burning money every quarter is not easy for him.

BUY

In general, he does not like Biotech's but he likes this company a lot. Looking at introducing therapy into the Alzheimer's stage, which would be disease altering, which would reverse the effects. Have good US partners. Likes for the long term.

BUY ON WEAKNESS

In diabetes and Alzheimer therapies. Alzheimer is a disease-altering drug, not just the symptoms. Could be 5 to 10 years. If you can, trade around the volatility. Excellent long-term upside.

BUY

In diabetes, but their big upside now is in their Alzheimer’s work. Their therapy is the only one that could be disease changing, not just the symptoms. It will take 5-7 years to prove it out.

STRONG BUY

Generally stays away from pure biotech. Interesting diabetes play, but likes it for the Alzheimer’s play. Has a drug that could be disease altering as opposed to symptom altering. It’ll be years before it comes through as a drug, but if it does, sales will be massive.

HOLD

Wouldn't be the best company in the biotechnology space. Not a bad company.

BUY

Has been consolidating around the $1 for some time. Seeing some selling pressures re: warrants that were converted. A relatively high risk name, but if they are successful across one or two of the different platforms they have, stock could be significantly higher. Good management team.

BUY

Likes the company. Even though it hasn't done a whole lot, it's starting to form a pretty good base. Now that the sector is a little bit better than it was, it is pretty ownable now.

BUY

Has a few products, but has one primary product in diabetes. If he gets it right, and the animal studies come through in humans, thinks the stock will go from $1 to over $10. The good news is that it has 2/3 other products coming up behind it, so if it drops, will only go down to $0.50.

BUY

Best to own a basket when owing smaller bio techs. Gigh risk/high return. Their diabetes drug, if it flows through, has a huge market potential. News flow has been fairly good. Still early stage. Good management.

BUY ON WEAKNESS

A pretty decent company. Got smeared with the same brush as Conjuchem. Doesn't expect anything this year as it will probably be sold as a tax loss. OK for the long term.

BUY ON WEAKNESS

Very solid management. A phase 2 drug. Overvalued considering the biotech market has dropped so much. Would be more interesting at $.80/$.90.

TOP PICK

Biotech world has had a tough time in the last month. This company is progressing well. Will take over the clinical development which is very lucrative for the company. Likes management and their pipeline.

TOP PICK

Has an interesting pipeline of products. An early stage product is a diabetes treatment.

BUY

Have the best animal model data that he has ever seen. If they can make the transition to human models, the stock would go to $10. Results could be out by the end of this year or the beginning of next.

Showing 1 to 15 of 17 entries

Transition Therapeutics Inc (TTH.TO) Frequently Asked Questions

What is Transition Therapeutics Inc stock symbol?

Transition Therapeutics Inc is a OTC stock, trading under the symbol TTH.TO (previously TTH-T on Stockchase) on the undefined (undefined). It is usually referred to as or TTH.TO

Is Transition Therapeutics Inc a buy or a sell?

In the last year, no analyst issued a Buy, Sell, or Hold rating on TTH.TO (previously TTH-T on Stockchase) on Stockchase. Read the latest expert commentary for Transition Therapeutics Inc.

Is Transition Therapeutics Inc a good investment or a top pick?

Transition Therapeutics Inc was recommended as a Top Pick by Hugh McCauley on 2004-05-13. Read the latest stock experts ratings for Transition Therapeutics Inc.

Why is Transition Therapeutics Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Transition Therapeutics Inc.

Is Transition Therapeutics Inc worth watching?

Transition Therapeutics Inc is covered by Stockchase experts and is worth watching.

Most Recent Experts

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Gordon Reid

GoodReid Investment Counsel

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Transition Therapeutics Inc (TTH.TO)